Liposome News and Research

Latest Liposome News and Research

Study finds novel delivery method that helps dissolve stroke-causing clots

A new study from the University of Cincinnati has found that, when delivered via ultrasound, the natural enzyme plasmin is more effective at dissolving stroke-causing clots than the standard of care, recombinant tissue plasminogen activator (rt-PA).

16 May 2013

ORAEs increase costs of care, hospital stays and risks of readmission and mortality, research finds

Pacira Pharmaceuticals, Inc. today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital healthcare system and received opioids for postsurgical pain management.

25 Apr 2013

New data reveals impact of opioid-related adverse events on length, cost of hospitalization after surgery

Pacira Pharmaceuticals, Inc. today announced data from a large-scale analysis of a national database of patients from 380 hospitals in the United States who underwent 319,898 inpatient surgeries and received opioids for postsurgical pain management.

27 Mar 2013

Scientists develop new chemo drug that fights cancer without impacting fertility

A new gentler chemotherapy drug in the form of nanoparticles has been designed by Northwestern Medicine- scientists to be less toxic to a young woman's fertility but extra tough on cancer. This is the first cancer drug tested while in development for its effect on fertility using a novel in vitro test.

25 Mar 2013

Research findings could lead to development of new drugs for gout treatment

Findings from a Loyola University Chicago Stritch School of Medicine study could lead to the development of new drugs to treat gout.

20 Mar 2013

Liposomes not capable of transporting themselves deep into the skin

Liposomes are small fat capsules, often added to beauty products. According to the beauty industry liposomes are capable of transporting active ingredients deep into the skin and release the active ingredients so that they can alter the skin-s structure by rejuvenating and smoothing the skin.

20 Feb 2013

New drug delivery system can reduce size of ovarian tumors by as much as 83%

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.

13 Feb 2013

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.

5 Feb 2013

Sun Pharma receives FDA approval for generic Doxil

The U.S. Food and Drug Administration today approved the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection).

4 Feb 2013

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

Celsion Corporation, a leading oncology drug development company, today announced that ThermoDox in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.

31 Jan 2013

New method allows controlled release of drugs; could help develop targeted treatments

Researchers have discovered a method that allows for the controlled release of an active agent on the basis of a magnetic nanovehicle.

25 Jan 2013

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

New gene delivery vehicle opens route to the heart of cells in solid tumors

There are plenty of effective anticancer agents around. The problem is that, very often, they cannot gain access to all the cells in solid tumors. A new gene delivery vehicle may provide a way of making tracks to the heart of the target.

15 Nov 2012

Azaya Therapeutics commences ATI-0918 bioequivalence study in ovarian cancer

Azaya Therapeutics, Inc. today announced the initiation of a bioequivalence study of ATI-0918 in patients with ovarian cancer.

25 Oct 2012

FDA approved drug to treat Ph- acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing form of blood and bone marrow cancer that is more commonly diagnosed in children than adults.

10 Aug 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).